New cancer drug enters first human trials for multiple tumor types
NCT ID NCT06751329
Summary
This is the first human study of an experimental cancer drug called DM002 for people with advanced solid tumors including ovarian, prostate, endometrial, and colorectal cancers. The study has two parts: first finding the safest dose, then testing that dose to see how well it works against cancer. Researchers will monitor how patients' bodies process the drug and track any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Care Wollongong
RECRUITINGWollongong, New South Wales, 2500, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Scientia Clinical Research
RECRUITINGRandwick, New South Wales, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Southern Oncology Clinical Research Unit
RECRUITINGAdelaide, South Australia, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Texas, MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Oklahoma Health Sciences Center
RECRUITINGOklahoma City, Oklahoma, 73190, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.